Clinical Trials

Study Title:
A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

For more information about the trial above please contact the study team: Medical University of South Carolina Principal Investigator, Theodore Gourdin, at gourdith@musc.edu. Study Coordinator, Carly Fecio, at fecio@musc.edu. Trial opened at the following institutions: Medical University of South Carolina